SCSarah M. Carnila

Sarah M. Carnila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah M. Carnila has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Snorkel Stenting During Transcatheter Aortic Valve Implantation: A Single-Center Study

    by Massimo Baudo, Serge Sicouri, Yoshiyuki Yamashita, Dimitrios E. Magouliotis, Francesco Cabrucci, Sarah M. Carnila, Scott M. Goldman, Eric M. Gnall, William A. Gray, Sandro Gelsomino, et al.

    Background and Objectives: Coronary obstruction (CO) is a potentially fatal complication that can occur during transcatheter aortic valve implantation (TAVI). The snorkel stenting technique was developed to mitigate the risk of CO. The aim of the current study was to evaluate the safety and clinical outcomes of snorkel stenting in patients at high risk of developing CO. Materials and Methods: All patients undergoing TAVI with snorkel stenting between January 2018 and December 2023 were retrospectively included. The primary outcome was the evaluation of perioperative CO and myocardial infarction (MI) at follow-up. Results: Between 2018 and 2023, a total of 1476 TAVI procedures were conducted, with 21 patients undergoing snorkel stenting for CO prevention. Median STS was 5.0 [IQR 3.0–8.0]. Four patients (19.0%) had a history of prior percutaneous coronary intervention, and 85.7% (n = 18) had a degenerated bioprosthesis. Preoperative multidetector CT revealed a mean sinus of Valsalva diameter of 24.6 ± 6.8 mm and a mean annulus area of 402.0 ± 59.7 mm2. The mean heights of the left and right coronary ostia were 7.9 ± 3.3 mm and 10.6 ± 5.5 mm, respectively. Nine patients (42.9%) presented with severe aortic regurgitation. Snorkel stenting was performed on the left main coronary in nine cases, on the right coronary in 10 cases, and on both the left main and right coronary arteries in two cases. No procedural complications were observed. Postoperatively, there were no MIs; one patient suffered from a disabling stroke, and another patient required a new pacemaker implant. Thirty-day mortality rate was 0%. At a median follow-up of 1.25 years (IQR: 1.05–3.05), there were five rehospitalizations for heart failure, no aortic valve reinterventions, one disabling stroke (sub-acute), and one MI. Overall, four patients died, including two cardiovascular-related deaths. Conclusions: Snorkel stenting should be considered for selected high- or prohibitive-surgical-risk patients undergoing TAVI who are at increased risk of developing CO. This technique showed favorable procedural outcomes for preventing CO occurring during or in the perioperative period of TAVI procedures. The abstract of the present study was accepted for oral presentation at the New York Valves on 26 June 2025.


  • Open Access

    Evolution of Untreated Moderate Mitral Regurgitation After Transcatheter Aortic Valve Implantation

    by Massimo Baudo, Serge Sicouri, Francesco Cabrucci, Yoshiyuki Yamashita, Dimitrios E. Magouliotis, Sarah M. Carnila, Sandra V. Abramson, Katie M. Hawthorne, Harish Jarrett, Roberto Rodriguez, et al.

    Background and Objectives: Associated mitral regurgitation (MR) is frequently observed during transcatheter aortic valve implantation (TAVI). The progression of moderate MR remains undetermined, given uncertain clinical significance and natural history. This study aims to assess the evolution of moderate MR following TAVI. Materials and Methods: Between 2018 and 2023, 1476 patients underwent TAVI. We excluded those with previous aortic or mitral valve interventions, endocarditis, concomitant percutaneous coronary intervention, or emergent procedures. Patients with severe aortic or tricuspid regurgitation or significant mitral stenosis were excluded. Ultimately, only patients with moderate MR were included, resulting in a final population of 154 patients. Results: Mean age was 81.4 ± 7.8 years, 48.1% (74/154) were female, and 48.1% (74/154) were functional MR. There was one surgical conversion due to annular rupture. Thirty-day mortality was 1.9% (3/154). Postoperative echocardiography showed 38 (24.7%) patients with none/trace MR, 91 (59.1%) with mild MR, 22 (14.3%) with moderate MR, and 3 (1.9%) with severe MR. Finally, according to the echocardiographic follow-up [median follow-up 1.0 (IQR: 0.1–1.2) years], 20.1% (31/154) had no/trace MR, 39.6% (61/154) had mild MR, 35.7% (55/154) had moderate MR, and 4.5% (7/154) had severe MR. Overall, 67 (43.5%) patients had any MR grade progression, 62 (40.3%) had stable disease, and 25 (16.2%) had any MR grade reduction at the last follow-up from the operation. No difference in MR evolution was seen between functional and primary MR. Conclusions: Concomitant moderate MR during TAVI has a variable evolution over time. A more detailed characterization of patients with preoperative moderate MR undergoing TAVI is necessary to identify those with a disease progression risk.